Fact sheet: JB Mltstck Hlth Innvtn

Fund information
Fund name
JB Multistock Health Innovation B USD
Fund manager company
GAM (Luxembourg) S.A.
Fund type
Offshore Fund
Fund managers
  • Christophe Eggmannsince 01/11/2010
Fund objective
The fund seeks to achieve long-term capital growth by investing globally in innovation-driven companies active in all health-care sub-sectors (pharmaceuticals, biotechnology, health-care services & supplies, medical technology, specialty pharmaceuticals and generics). The actively managed fund is suitable for equity investors with a long-term horizon and appropriate risk awareness who wish to complement their portfolio with a concentrated investment in the health-care sector.
Benchmark
  • Cust. MSCI World Health Care ND
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
-5%
1 Year rank in sector
24/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.81%
Fund size
£203m (£251m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
132
Top in this sector
Fund name1 Year
Variopartner SICAV MVGbMdtcF23%
BB Medtech21.2%
Fidelity Gbl Health Care18%
Charlemagne MagnaBiphrm16.5%
Pictet Health16.4%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA91%
    Money Market3.6%
    Switzerland3.5%
    Denmark1.4%
    France0.4%
  • Biotechnology/Medical36.9%
    Pharmaceuticals31.6%
    Healthcare & Medical Products13%
    Health Care9.9%
    Money Market3.6%
  • US Equities91%
    Money Market3.6%
    Swiss Equities3.5%
    Danish Equities1.4%
    French Equities0.4%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund2.4%5.7%8.9%-5%37.6%203.5%
Sector3.6%10.5%13.3%-0.9%42.4%136.8%
Rank within sector19 / 3224 / 3222 / 3124 / 3113 / 242 / 24
Quartile3rd3rd3rd4th3rd1st
Calendar performance
 YTD - 20162015201420132012
Fund-10%9.1%32.2%64.9%26.9%
Sector-2.9%7.2%28.1%41%16.7%
Rank within sector24 / 3115 / 2917 / 261 / 245 / 24
Quartile4th3rd3rd1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-0.36
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.02
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.51
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
17.43
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
6.3
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.06
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.87
Price movement
52 week high352.44
52 week low276.63
Current bid price-
Current offer price-
Current mid price312.41
Region
1USA90.99%
2Money Market3.64%
3Switzerland3.53%
4Denmark1.39%
5France0.42%
6Japan0.03%
Industry sector
1Biotechnology/Medical36.9%
2Pharmaceuticals31.62%
3Healthcare & Medical Products13%
4Health Care9.85%
5Money Market3.64%
6Food & Drug Retailers2.68%
7Hospital1.95%
8Internet0.36%
Asset type
1US Equities90.99%
2Money Market3.64%
3Swiss Equities3.53%
4Danish Equities1.39%
5French Equities0.42%
6Japanese Equities0.03%
Individual holdings
1JOHNSON & JOHNSON8.43%
2GILEAD SCIENCES INC5.96%
3PFIZER INC5.17%
4ALLERGAN PLC4.79%
5HOLOGIC INC4.32%
Management
Fund manager group
Swiss&Gbl Asset Management
Fund manager company
GAM (Luxembourg) S.A.
Fund type
Offshore Fund
Fund objective
The fund seeks to achieve long-term capital growth by investing globally in innovation-driven companies active in all health-care sub-sectors (pharmaceuticals, biotechnology, health-care services & supplies, medical technology, specialty pharmaceuticals and generics). The actively managed fund is suitable for equity investors with a long-term horizon and appropriate risk awareness who wish to complement their portfolio with a concentrated investment in the health-care sector.
Benchmark
  • Cust. MSCI World Health Care ND
Investment style
Growth
Investment method
Shares
Fund managers
NameSinceBiography
Christophe Eggmann01/11/2010Christophe Eggmann is Portfolio Manager of the JB Health Innovation Fund. Prior to joining GAM Group in November 2010, he was Head of Equity Research at Julius Baer and equity analyst covering the global healthcare sector. Prior to that, he held various positions as a fund manager and equity analyst at Bank Hofmann, Rothschild Bank and Credit Suisse. Christophe Eggmann holds a Master in Business Administration and Economics from the University of Neuchâtel and is a CFA Charterholder. He is based in Zurich.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Transparent for German Tax, IA Recognised, Reporting Fund Status, UCITS IV Compliant, UCITS V Compliant
Domicile
No data available.
Fund for sale in
Austria, Belgium, Bulgaria, Switzerland, Germany, Denmark, Spain, Estonia, Finland, France, United Kingdom, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Netherlands, Norway, Offshore, Singapore, Sweden
JB Multistock Health Innovation A USD
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.81%
Total expense ratio (TER)1.8%
Bid price-
Offer price-
Mid price309.68
CurrencyUSD
Price updated23/09/2016
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeBKO5
JB Multistock Health Innovation B USD
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£5,000
Available in ISANo
Ongoing charge (OCF)1.81%
Total expense ratio (TER)1.8%
Bid price-
Offer price-
Mid price312.41
CurrencyUSD
Price updated23/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBKO8
JB Multistock Health Innovation BH EUR
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.8%
Total expense ratio (TER)1.8%
Bid price-
Offer price-
Mid price90.76
CurrencyEUR
Price updated23/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFWXV
JB Multistock Health Innovation C USD
Initial charge5%
Annual charge0.85%
Min single investment£500,000
Min regular saving£100,000
Available in ISANo
Ongoing charge (OCF)1.2%
Total expense ratio (TER)1.2%
Bid price-
Offer price-
Mid price331.23
CurrencyUSD
Price updated23/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeBKP1
JB Multistock Health Innovation E CHF
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price95.22
CurrencyCHF
Price updated17/02/2010
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBKP2
JB Multistock Health Innovation E USD
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£100,000
Available in ISANo
Ongoing charge (OCF)2.57%
Total expense ratio (TER)2.55%
Bid price-
Offer price-
Mid price293.39
CurrencyUSD
Price updated23/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBKP4
JB Multistock Health Innovation Eh EUR
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.55%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price106.6
CurrencyEUR
Price updated23/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeE68O
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.